

ASX Announcement

7 October 2020

Regeneus to be granted new Sygenus patent in Canada

Highlights:

- The Canadian Intellectual Property Office has issued a notice of allowance for a new patent for Sygenus for the treatment of acne
- The granted patent will provide commercial rights in Canada through to 2032
- Key Sygenus patents now cover all key target markets, including the U.S., Japan, Europe, Australia, and now Canada
- Patent expands the potential application of the platform technology into the US\$10.9 billion global acne medication market¹

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for issuance of a new key patent for the Company's Secretome technology platform, Sygenus, in Canada.

The patent to be granted covers topical treatment of acne using adipose tissue-derived secretions.

Sygenus is a topical serum and gel treatment for pain and inflammation conditions composed of selective bioactive molecules from the stem cell secretome. It has been shown in human pilot studies to improve the appearance of acne, non-inflammatory lesions – such as blackheads and whiteheads – as well as inflammatory papules. Safety and tolerability were also demonstrated (refer to announcement on 6 February 2018).

This announcement follows the Company's U.S patent announcement for non-inflammatory skin conditions, including age spots, wrinkles, and other age-related conditions (refer to announcement on 19 August 2020).

"This patent supports the diverse opportunity of our Secretome-only technology platform Sygenus and expands its potential to address a globally prevalent skin condition like acne," said Regeneus CEO and Executive Director Leo Lee.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on

¹ Acne Medication Market by Therapeutic Class. Allied Market Research
<https://www.alliedmarketresearch.com/acne-medication-market>.

neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications

T: 02 9237 2805

E: WE-AURegeneus@we-worldwide.com